— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected.
— Revenues grew 62% to $94.6 million, vs. $88.4 million expected.
— Research and development expenses were $62.6 million, compared to $53.1 million last year.
— FY19 NUPLAZID net sales guidance is increased to $330 million to $340 million from the previous range of $320 million to $330 million.
— ACAD shares fell 0.81% following the announcement.
For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected
Shares of Macy’s Inc. (NYSE: M) were down on Thursday. The stock has gained 36% over the past three months and 18% over the past one month. The company’s sales
Department store chain The Kroger Co. (NYSE: KR) on Thursday said its third-quarter sales and adjusted earnings increased year-over-year. The latest numbers also exceeded the market's expectations. Net earnings attributable to